MDedgeHemOnc Profile Banner
MDedge Hematology & Oncology Profile
MDedge Hematology & Oncology

@MDedgeHemOnc

Followers
8K
Following
289
Media
4K
Statuses
11K

MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.

Rockville, MD, Parsippany, NJ
Joined June 2009
Don't wanna be here? Send us removal request.
@MDedgeHemOnc
MDedge Hematology & Oncology
4 years
Bookmark this long COVID resource center for #HemOnc. https://t.co/8QeEhORgMX
0
0
5
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer https://t.co/JxQr1j7tmQ
0
0
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
#ASCO23 Many patients with locally advanced rectal cancer who do not have high-risk disease can skip radiotherapy to the pelvic area, and instead be treated with chemotherapy alone and then surgery, say researchers reporting results from the PROSPECT trial https://t.co/dBzlnv0Wmh
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
New results in the treatment of advanced ovarian cancer have been welcomed by an expert not involved in the trial, even though the study showed only an improvement in PFS, not yet overall survival. https://t.co/pW3J6QF8ug
0
0
1
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Ribociclib forestalls recurrence also in early breast cancer #ASCO23 https://t.co/k4wT6xtIFm
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Up-front pembro plus chemo boost survival in cervical cancer #ASCO23 https://t.co/PDok3RwMhj
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Oral drug for brain tumor could change treatment landscape https://t.co/dEcx99FZd8
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
A telephone-based weight loss intervention resulted in clinically meaningful weight loss in patients with breast cancer who were overweight and obese. #ASCO23 https://t.co/1yKwzRVkNJ
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Racial disparities in cancer care have been reduced by Medicaid expansion, suggest new nationwide data. #ASCO23 https://t.co/l3uonbVpSP
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Groundbreaking new regimen for advanced Hodgkin lymphoma #ASCO23 https://t.co/2plEYhGUNx
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Cross-border U.S.-Mexican collaboration drives up ALL survival #ASCO23 https://t.co/97sNvtaUJH
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Chemo avoidance pays off for some women with HER2+ early BC #ASCO23 https://t.co/WlMjbeg36H
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
SCLC: Bispecific antibody shows phase 1 promise #ASCO23 https://t.co/tDY52rCEDZ
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
🆕 meta-analysis of 25 studies dating back to 1948 provides more evidence linking ovarian suppression/ablation in premenopausal women to less recurrence and more survival in the long term after breast cancer. #ASCO23 https://t.co/malsdn9bxj
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Surgical de-escalation passes clinical test in low-risk #cervicalcancer #ASCO23 https://t.co/c7GCLandHW
0
1
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
People exposed to high levels of PFOS – a widely used synthetic chemical – run an increased risk of #HCC, researchers say. https://t.co/4Lgh3j7Shp
0
0
2
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
A live birth after the diagnosis of BC does not have a negative impact on a woman’s OS. https://t.co/mpEJrPkWAP
0
0
1
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of CRC. https://t.co/rYZYAHmbp1
0
0
0
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
Adding high-dose vitamin C to first-line chemotherapy does not significantly improve PFS in patients with mCRC but may benefit patients with RAS mutation. https://t.co/TVwkEllZSL
0
0
4
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
The real competition in medicine is not between companies. Rather it's us against disease. https://t.co/BiWSfglAir #Changemakers via @drjohnwhyte
0
0
1
@MDedgeHemOnc
MDedge Hematology & Oncology
3 years
#ICYMI THE NEW GASTROENTEROLOGIST's overview of therapeutic management of #NAFLD https://t.co/8g0i6PJLq4
0
0
1